atients with hypertension often develop left ventricular (LV) hypertrophy as a physical response to chronic pressure overload, and it can result in decreased chamber compliance and eventually lead to the deterioration of LV systolic function. Any of these changes contribute to the development of heart failure. Angiotensin II is now believed to play a critical role in the pathogenesis of hypertrophy and/or hyperplasia of vascular smooth muscle cells, 1-6 and angiotensin II receptor blockers (ARBs) are a new class of effective and well-tolerated orally active antihypertensive agents. 7 Recent clinical trials have shown various benefits of ARB therapy in hypertensive patients, including the reduction of LV hypertrophy, 6-17 improvement in diastolic function, 18 improvement in endothelial function 19-22 and a cardioprotective effect in patients with heart failure. [23] [24] [25] Candesartan cilexetil, a new angiotensin II type 1 (AT1) receptor blocker, shows strong and long-lasting binding to the AT1 receptor and thus provides 24-h control of blood pressure (BP) while blocking the major negative cardiovascular effects of angiotensin II. 10 The beneficial effects of candesartan have been reported, [5] [6] [7] [9] [10] [11] [12] [13] [14] [15] [16] [17] 21, 22 but there has not been a study that followed both cardiac status Circulation Journal Vol.66, November 2002 and endothelial function in hypertensive patients for up to 12 months. Accordingly, we instigated the present study of the effects of candesartan on LV function, LV hypertrophy, and endothelial function in patients with hypertensive heart disease (HHD) during a 1-year period.
flow] greater than 1 and a DcT (deceleration time of early diastolic transmitral flow) greater than 250 ms were the criteria of LV diastolic dysfunction and all participants satisfied the criteria.
Patients who were suspected to have hypertrophic cardiomyopathy (ie, LV asymmetrical hypertrophy or IVS thickness >15 mm or apical hypertrophy) on echocardiography were excluded. In addition, participants had to be free of any evidence of heart failure, ischemic heart disease, congenital or valvular heart disease, other cardiomyopathies, arrhythmias (chronic atrial fibrillation etc) or systemic disease (diabetes mellitus etc) that would influence cardiac function.
In group C, 8 patients had taken an antihypertensive agent (calcium antagonist only) over 1 year previously, and 15 had never received any antihypertensive drugs before this study. In group P, it was 4 patients and 2 patients, respectively. None of the patients had been treated with angiotensin-converting enzyme inhibitors or other ARBs before this study. We explained the details of the study to all the patients and they gave their informed consent.
Study Protocol
The patients received candesartan (8 mg/day) and echocardiography, equilibrium radionuclide ventriculography (RNVG) and evaluation of endothelial function were carried out before and after 3, 6, and 12 months of drug administration.
BP Measurement After a 10-min rest period, BP of the right brachial artery was measured using a mercury sphygmomanometer while the patient remained supine.
Echocardiography Echocardiography was performed using an ultrasonic sector scanner with 2.5-and 3.5-MHz transducers (SONOS 2000 Hewlett Packard, Boston, MA, USA). Standard parasternal long-and short-axis views and apical 2-and 4-chamber views were obtained in all patients. M-mode echocardiograms were derived from the 2-dimensional images. LV dimensions, wall thickness and cavity size were measured. LV mass was calculated from the Mmode echocardiography according to the method of Devereux and Reichek 26 and the LV mass index (LVMI) was calculated as LV mass/body surface area. The LV ejection fraction (LVEF) was calculated by the modified Simpson's method. 27 The LV filling velocities were recorded with pulse Dopplar echocardiography by an apical approach, together with a phonocardiogram, on a strip chart at a paper speed of 100 cm/s. The sample volume was set at the level of the mitral leaflet tip in diastole. The peak velocity of atrial filling (A) and early diastolic filling (E) and their ratio (A/E) were obtained (Fig 1) . The deceleration time (DcT) of the LV early filling wave was also measured. All measurements were carried out at end-expiration.
Radionuclide Ventriculography R wave-gated equilibrium blood pool studies were performed at rest to measure the LVEF fraction and peak filling rate. Images were acquired using a large field of view gamma camera and a medium-sensitivity parallel-hole collimator oriented in the 45°left anterior oblique projection with caudal tilt.
Measurement of Flow-Dependent Dilation Endothelial function was evaluated from the flow-dependent dilation (%FDD), 28 which was calculated as the percent change in the diameter of the radial artery (5 cm proximal to the wrist) of the nondominant arm during reactive hyperemia after upper arm occlusion. The radial artery diameter was measured using a high-resolution ultrasound system and the recordings were obtained with a 7.5-MHz transducer positioned perpendicular to the vessel; ultrasonic gel was applied to improve transmission. Occlusion was performed by inflating a cuff to 40 mmHg above systolic BP for 5 min and immediately after release of the cuff, the arterial diameter was measured.
Evaluation of the Effects of Candesartan
LV systolic function was assessed from the LVEF measured by echocardiography and radionuclide ventriculography, diastolic function was evaluated from the A/E ratio and the DcT on the Doppler echocardiographic studies, and the peak filling rate was assessed from the results of the radionuclide ventriculography. LV hypertrophy was assessed as the LVMI and the sum of the thicknesses of the IVS and posterior wall (PW) at end-diastole on M-mode echocardiography. Endothelial function was evaluated from the %FDD. Cardiac status was evaluated by the serum concentration of brain natriuretic peptide (BNP).
Statistical Analysis
Data are expressed as the mean ± SD. Comparisons of mean changes in groups C and P were performed by a 2-way ANOVA and post hoc test. Analysis of sequential changes was performed by repeated-measures ANOVA. Probability values of less than 0.05 were considered significant.
Results
All patients continued their treatment and no side effects related to candesartan were noted.
Characteristics of Group C (Tables 1, 2)
Group C consisted of 14 men and 9 women aged 63±11 years (mean ± SD). Their body mass index was 23.6± 1.5 kg/m 2 and they had had hypertension for 2.8±1.8 years. Three patients were smokers (13%) and 3 had hyperlipidemia (13%). The systolic and diastolic BP values were 168±7 mmHg and 99±7 mmHg, respectively.
BP and Heart Rate The systolic and diastolic BP values were significantly (p<0.05) decreased after 3 months of candesartan therapy (Fig 2A) . The systolic BP had fallen by approximately 20 mmHg and the diastolic BP by approximately 10 mmHg at 3 months after administration and those levels were maintained for 1 year. However, there was no significant change in the heart rate: 70±8 beats/min before the study, 68±6 beats/min at 3 months, 67±7 beats/min at 6 months and 67±6 beats/min at 12 months after administration.
Echocardiographic Study The LV end-diastolic internal dimension (LVDd) was 47±5 mm and the end-systolic internal dimension (LVDs) was 30±4 mm before the study. The LVDd did not change significantly after administration ( Fig 2B) and although the LVDs had not improved after 3 months, it was significantly (p<0.05) improved after 6 months: 30±3 mm at 3 months, 28±3 mm at 6 months and 28±2 mm at 12 months after administration (Fig 2B) .
The sum of the thicknesses of the IVS and PW (IVS + PW) was 25.5±1.4 mm before the study, 24.8±1.3 mm at 3 months, 23.2±1.6 mm at 6 months and 22.7±1.5 mm at 12 months after administration. The IVS + PW had not improved after 3 months, but was significantly (p<0.05) improved after 6 months. The LVMI had the same result ( Fig 2C) : 169±25 g/m 2 before the study, 165±21 g/m 2 at 3 months, 147±15 g/m 2 at 6 months and 141±14 g/m 2 at 12 months after administration. The A/E ratio was significantly (p<0.05) improved at 3 months: 1.42±0.20 before the study, 1.26±0.20 at 3 months, 1.15±0.23 at 6 months and 1.04± 0.14 at 12 months after administration. The DcT was also significantly (p<0.05) improved at 3 months: 283±30 ms before the study, 259±25 ms at 3 months, 246±19 ms at 6 months and 235±14 ms at 12 months after administration. The LVEF on echocardiography was not improved after 3 months, but was significantly (p<0.05) improved at 6 months: 65±6% before the study, 66±5% at 3 months, 70± 5% at 6 months and 71±4% at 12 months after administration.
Results of Radionuclide Ventriculography The LVEF on radionuclide ventriculography (Fig 2D) , as on echocardiography, was not improved after 3 months, but was significantly (p<0.05) improved at 6 months. The peak filling rate was significantly (p<0.05) improved at 3 months (Fig 3A) .
Endothelial function (Fig 3B) The %FDD was significantly (p<0.05) improved at 3 months and, moreover, at 6 months, it had further significantly (p<0.05) improved compared with that at 3 months.
Serum Concentration of BNP (Fig 3C) The serum BNP was measured for 15 patients in group C and of those, 3 were in the normal range and the other 12 were above normal before the study. The BNP tended to decrease after candesartan administration. Characteristics of Group P (Table 3 ) Group P consisted of 5 men and 1 woman aged 72±5 years, which was older than the group C patients (p=0.06). Their body mass index was 23.0±1.6 kg/m 2 and they had had hypertension for 3.8±1.5 years. One patient was a smoker and one had hyperlipidemia. The systolic and diastolic BP values before candesartan administration were 178±2 mmHg and 101±8 mmHg, respectively. The systolic BP was significantly higher than that in group C (p<0.01).
BP and Heart Rate The systolic BP was significantly (p<0.05) decreased after 6 months (174±4 mmHg) of candesartan therapy (Fig 4A) , falling by approximately 4 mmHg. The diastolic BP was unchanged (Fig 4B) . There was no significant change in heart rate: 69±7 beats/min before the study, 68±6 beats/min at 3 months and 69± 8 beats/min at 6 months after administration.
Echocardiographic Study The LVDd was 49±2 mm and LVDs was 31±3 mm before the study and there were no significant difference between groups P and C. The LVDd did not changed significantly after administration (Fig 4C) . The LVDs had not improved after 3 months, but was significantly (p<0.05) improved after 6 months: 32±4 mm and 29±3 mm, respectively (Fig 4D) .
The IVS + PW was 26.5±1.0 mm and the LVMI was 194±31 g/m 2 before the study. There was no significant difference between groups P and C, although the LVMI of group P tended to higher than that of group C (p=0.051). The IVS + PW was 25.9±0.7 mm at 3 months and 25.2± 0.5 mm at 6 months after administration, and the LVMI was 185±27 g/m 2 and 175±20 g/m 2 , respectively (Fig 5A) . The IVS + PW and the LVMI were not improved after 3 months, but were significantly (p<0.05) improved after 6 months. The A/E ratio was 1.62±0.12 and the DcT was 292± 14 ms before the study. There was no significant difference between groups P and C regarding the DcT before administration; however, the A/E ratio of group P was significantly (p<0.05) higher than that of group C. The A/E ratio was significantly (p<0.05) improved at 3 months: 1.54±0.14 at 3 months and 1.44±0.15 at 6 months after administration. The DcT was also significantly (p<0.05) improved at 3 months: 279±18 ms and 260±9 ms respectively.
The LVEF on echocardiography was 65±5% before the study and there was no significant difference between groups P and C. It had not improved after 3 months, but was significantly (p<0.05) improved at 6 months: 64±4% and 69±4% respectively.
Results of Radionuclide Ventriculography The LVEF on radionuclide ventriculography was 64.0±5.4% before the study ( Fig 5B) and there was no significant difference between groups P and C. As with the results on echocardiography, the LVEF was not improved after 3 months, but was significantly (p<0.05) improved at 6 months (64.7±3.8% and 69.1±3.9%, respectively). The peak filling rate was 229±14%/s before the study ( Fig 5C) and there was no significant difference between groups P and C. It was significantly (p<0.05) improved at 3 months (246±20%/s) and at 6 months (271±14%/s) after administration. Endothelial Function (Fig 5D) The %FDD of group P was 3.6±1.1% before the study and was significantly lower than that of group C (p<0.05). It had not improved after 3 months, but was significantly (p<0.05) improved at 6 months (4.3±1.7% and 6.8±1.6%, respectively).
Serum concentration of BNP (Fig 5E) The serum BNP of group C was 41.0±8.2 pg/ml before the study and did not improve after 3 months; however, it was significantly (p< 0.05) improved at 6 months (36.8±10.6 pg/ml and 31.0± 9.6 pg/ml, respectively).
Discussion

Antihypertensive Effect of Candesartan
In the present study, systolic BP decreased by approximately 20 mmHg and diastolic BP by 10 mmHg on average at 12 months after administration of candesartan. However, other clinical studies on patients with HHD have shown equivalent or better BP responses. 9, 21 Israili reported that the antihypertensive potency of ARBs was in the following order (based upon the starting dose in milligrams): candesartan cilexetil > telmisartan = losartan > irbesartan = valsartan > eprosartan. 7 
Improvement of Cardiac Function and LV Hypertrophy
In patients with HHD, the beneficial effect of losartan on diastolic function has already been reported, 18 but not the the effect of candesartan. Also, improvement of systolic function has never been documented after administration of ARBs. Our study showed candesartan improved both diastolic and systolic LV function, LV diastolic function first, then the systolic function, even though the present subjects had relatively good LV contraction before treatment. This indicates that candesartan has a beneficial effect on cardiac function in patients with HHD.
Angiotensin II acts as a potent growth factor for vascular smooth muscle cells and cardiac myocytes, [1] [2] [3] [4] [5] [6] so blocking the angiotensin II receptor with a selective angiotensin II receptor 1 antagonist has a therapeutic benefit in patients with hypertensive LV hypertrophy. There is clinical evidence of significant efficacy of treatment with ARBs in reversing the LV hypertrophy of hypertensive patients. [5] [6] [7] [9] [10] [11] [12] [13] [14] [15] [16] [17] Candesartan has been shown to induce regression of LV hypertrophy within 8-12 weeks of starting treatment, 9, 13, 16 but in the present study, that was not significant until after 6 months of treatment.
The increase in LV mass in patients with hypertension is not only because of transverse and longitudinal enlargement of the cardiomyocytes, but also to alterations of the vasculature and intercellular matrices. 6, [29] [30] [31] candesartan caused a decrease of LV weight, cardiomyocyte size, and LV interstitial collagen volume fraction in the hearts of stroke-prone spontaneously hypertensive rats, and prevented or caused the regression of myocardial fibrosis in adult rats. 13 These results suggest that candesartan may cause regression of LV hypertrophy and improve cardiac function.
Improvement of Endothelial Function
Patients with essential hypertension have endothelial dysfunction is characterized by impaired basal and agonistevoked nitric oxide release and an increase in endothelin-1-induced vasoconstriction. 21, [32] [33] [34] [35] [36] [37] Endothelial dysfunction can affect the cardiovascular system in 2 ways: (1) dysfunction of resistance vessels may impair peripheral perfusion, and (2) dysfunction of large conduit vessels may limit the increase of blood flow provided and increase the impedance that needs to be overcome by the LV and consequently impair LV ejection. 28 Endothelial function can be evaluated by measuring flow-dependent dilation with a high-resolution ultrasound system. 28 Ghiadoni et al reported that treatment with candesartan increased tonic nitric oxide release and reduced the vasoconstricting effect of endogenous endothelin-1 in the forearm of patients with essential hypertension, 21 indicating that candesartan improves endothelial function, although the effect was not seen after 2 months of treatment with candesartan, but revealed itself after 12 months. 21 We did not directly evaluate nitric oxide and endothelin-1, but %FDD is mediated by nitric oxide and our results indicate that endothelial function was improved after 3 months of drug administration. Moreover, endothelial function showed significantly more improvement at 6 months compared with 3 months, and the improvement lasted until 12 months.
Candesartan Improves Cardiac Function, LV Hypertrophy and Endothelial Function
This study demonstrated that patients with HHD who were given candesartan showed improvement in LV systolic and diastolic function, LV hypertrophy, serum concentration of BNP and endothelial function, even if BP control was poor. The results indicate that candesartan itself can improve these parameters.
Possibility of Reduced Mortality and Morbidity
The possibility of reduced mortality and morbidity from the regression of LV hypertrophy in patients with hypertension is an important consideration, because LV hypertrophy is associated with increased mortality 6, 10, 38 as well as an increased risk of nonfatal cardiovascular complications. 39 As outlined by Devereux et al, there is a consistently higher risk of morbid events in subjects with LV hypertrophy when compared with subjects who do not have hypertrophy. 40 Also, morbid events occur in a higher proportion of subjects with progressive LV hypertrophy when compared with those in whom hypertrophy shows regression. Several studies have provided information on the relationship between the regression of LV hypertrophy and subsequent morbidity and mortality, [41] [42] [43] and the present findings indicate that candesartan may reduce the mortality and morbidity of the patients with hypertensive LV hypertrophy.
